Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm‐Associated Infections,ChemMedChem

当前位置： X-MOL 学术 › ChemMedChem › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm‐Associated Infections
ChemMedChem ( IF 3.6 ) Pub Date : 2020-10-14 , DOI: 10.1002/cmdc.202000677
Stella Cascioferro ₁ , Daniela Carbone ₁ , Barbara Parrino ₁ , Camilla Pecoraro ₁ , Elisa Giovannetti _{2,

3} , Girolamo Cirrincione ₁ , Patrizia Diana ₁

Affiliation

Methicillin‐resistant Staphylococcus aureus (MRSA) has emerged as one of the leading causes of persistent human infections. This pathogen is widespread and is able to colonize asymptomatically about a third of the population, causing moderate to severe infections. It is currently considered the most common cause of nosocomial infections and one of the main causes of death in hospitalized patients. Due to its high morbidity and mortality rate and its ability to resist most antibiotics on the market, it has been termed a “superbug”. Its ability to form biofilms on biotic and abiotic surfaces seems to be the primarily means of MRSA antibiotic resistance and pervasiveness. Importantly, more than 80 % of bacterial infections are biofilm‐mediated. Biofilm formation on indwelling catheters, prosthetic devices and implants is recognized as the cause of serious chronic infections in hospital environments. In this review we discuss the most relevant literature of the last five years concerning the development of synthetic small molecules able to inhibit biofilm formation or to eradicate or disperse pre‐formed biofilms in the fight against MRSA diseases. The aim is to provide guidelines for the development of new anti‐virulence strategies based on the knowledge so far acquired, and, to identify the main flaws of this research field, which have hindered the generation of new market‐approved anti‐MRSA drugs that are able to act against biofilm‐associated infections

中文翻译：

对抗 MRSA 生物膜相关感染中抗生素耐药性的治疗策略

耐甲氧西林金黄色葡萄球菌(MRSA) 已成为人类持续感染的主要原因之一。这种病原体很普遍，能够在大约三分之一的人口中无症状地定殖，导致中度至重度感染。它目前被认为是医院感染的最常见原因，也是住院患者死亡的主要原因之一。由于其高发病率和死亡率以及对市场上大多数抗生素的抵抗能力，它被称为“超级细菌”。它在生物和非生物表面形成生物膜的能力似乎是 MRSA 抗生素耐药性和普遍性的主要手段。重要的是，超过 80% 的细菌感染是生物膜介导的。留置导管上的生物膜形成，假肢装置和植入物被认为是医院环境中严重慢性感染的原因。在这篇综述中，我们讨论了过去五年中最相关的文献，这些文献涉及开发能够抑制生物膜形成或根除或分散预先形成的生物膜以对抗 MRSA 疾病的合成小分子。目的是根据迄今为止所获得的知识为开发新的抗毒力策略提供指导，并确定该研究领域的主要缺陷，这些缺陷阻碍了新的市场批准的抗 MRSA 药物的产生。能够对抗生物膜相关感染在这篇综述中，我们讨论了过去五年中最相关的文献，这些文献涉及开发能够抑制生物膜形成或根除或分散预先形成的生物膜以对抗 MRSA 疾病的合成小分子。目的是根据迄今为止所获得的知识为开发新的抗毒力策略提供指导，并确定该研究领域的主要缺陷，这些缺陷阻碍了新的市场批准的抗 MRSA 药物的产生。能够对抗生物膜相关感染在这篇综述中，我们讨论了过去五年中最相关的文献，这些文献涉及开发能够抑制生物膜形成或根除或分散预先形成的生物膜以对抗 MRSA 疾病的合成小分子。目的是根据迄今为止所获得的知识为开发新的抗毒力策略提供指导，并确定该研究领域的主要缺陷，这些缺陷阻碍了新的市场批准的抗 MRSA 药物的产生。能够对抗生物膜相关感染

更新日期：2020-10-14

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11